The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells

International Journal of Molecular Medicine

Volumn 30, Issue 4, 2012, Pages 856-862

  Zhang, Zhe ^a,b   Liu, Ze Bing ^b   Ren, Wei Min ^b   Ye, Xuan Guang ^b   Zhang, You Yuan ^b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Anaplastic thyroid cancer cell; Epidermal growth factor; Epidermal growth factor receptor; Epithelial mesenchymal transition; miR 200

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA 200; UVOMORULIN; VIMENTIN;

ANAPLASTIC THYROID CANCER; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID FOLLICLE CELL; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CADHERINS; CELL LINE; CELL LINE, TUMOR; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RHOA GTP-BINDING PROTEIN; RNA INTERFERENCE; THYROID GLAND; THYROID NEOPLASMS; VIMENTIN;

EID: 84866507849     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1059     Document Type: Article

References (28)

1. Riesco-Eizaguirre G and Santisteban P: New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer 14: 957-977, 2007. (Pubitemid 351252429)
2. Patel KN and Shaha AR: Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13: 119-128, 2006.
3. Zhong WB, Liang YC, Wang CY, Chang TC and Lee WS: Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr Relat Cancer 12: 615-629, 2005.
4. Larue L and Bellacosa A: Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 30 kinase/AKT pathways. Oncogene 24: 7443-7454, 2005. (Pubitemid 41637984)
5. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
6. Christiansen JJ and Rajasekaran AK: Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66: 8319-8326, 2006. (Pubitemid 44449137)
7. Bergstrom JD, Westermark B and Heldin NE: Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res 259: 293-299, 2000.
8. Kuan CT, Wikstrand CJ and Bigner DD: EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8: 83-96, 2001. (Pubitemid 32641351)
9. Larsen AK, Ouaret D, El Ouadrani K and Petitprez A: Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 131: 80-90, 2011.
10. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, et al : Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 121: 1313-1328, 2011.
11. Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, Llorens RD and Colomer R: An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol Med 20: 3-10, 2007.
12. Sanz-Moreno V, Gaggioli C, Yeo M, Albrengues J, Wallberg F, Viros A, Hooper S, Mitter R, Féral CC, Cook M, et al: ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 20: 229-245, 2011.
13. Zhang Z, Ren JH, Li ZY, Nong L and Wu G: Fasudil inhibits lung carcinoma-conditioned endothelial cell viability and migration. Oncol Rep 27: 1561-1566, 2012.
14. Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R, Bird D and Marshall CJ: ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 9: 33-44, 2006. (Pubitemid 43069509)
15. Zhong WB, Hsu SP, Ho PY, Liang YC, Chang TC and Lee WS: Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway. Biochem Pharmacol 82: 1663-1672, 2011.
16. Kidera Y, Tsubaki M, Yamazoe Y, Shoji K, Nakamura H, Ogaki M, Satou T, Itoh T, Isozaki M, Kaneko J, et al: Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho- associated coiled-coil containing protein kinase pathway. J Exp Clin Cancer Res 29: 127, 2010.
17. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, Klijn JG, Wiemer EA and Martens JW: Four miRNAs associated with aggressiveness of lymph node-negative estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 105: 13021-13026, 2008.
18. Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688, 2007. (Pubitemid 47552092)
19. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601, 2008. (Pubitemid 351627379)
20. Park SM, Gaur AB, Lengyel E and Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22: 894-907, 2008. (Pubitemid 351482843)
21. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR and Sarkar FH: miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 27: 1712-1721, 2009.
22. Yin L, Morishige K, Takahashi T, Hashimoto K, Ogata S, Tsutsumi S, Takata K, Ohta T, Kawagoe J, Takahashi K and Kurachi H: Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther 6: 1517-1525, 2007. (Pubitemid 46954018)
23. Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481, 1999. (Pubitemid 29220854)
24. Umemura S, Itoh J, Itoh H, Serizawa A, Saito Y, Suzuki Y, Tokuda Y, Tajima T and Osamura RY: Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol 12: 8-13, 2004. (Pubitemid 38332312)
25. Wunderlich A, Fischer M, Schlosshauer T, Ramaswamy A, Greene BH, Brendel C, Doll D, Bartsch D and Hoffmann S: Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer. Cancer Sci 102: 762-768, 2011.
26. Ying H, Biroc SL, Li WW, Alicke B, Xuan JA, Pagila R, Ohashi Y, Okada T, Kamata,Y and Dinter H: The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 5: 2158-2164, 2006. (Pubitemid 44530451)
27. Cho HJ and Yoo J: Rho activation is required for transforming growth factor-beta-induced epithelial-mesenchymal transition in lens epithelial cells. Cell Biol Int 31: 1225-1230, 2007. (Pubitemid 47030990)
28. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, Kimura S, Kiyomoto H, Ohmori K, Li DT, Abe Y and Nishiyama A: Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 17: 2193-2201, 2006. (Pubitemid 44141909)